454 related articles for article (PubMed ID: 29193737)
1. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians.
Douxfils J; Ageno W; Samama CM; Lessire S; Ten Cate H; Verhamme P; Dogné JM; Mullier F
J Thromb Haemost; 2018 Feb; 16(2):209-219. PubMed ID: 29193737
[TBL] [Abstract][Full Text] [Related]
2. Direct oral anticoagulants (DOACs).
Vazquez S; Rondina MT
Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
[TBL] [Abstract][Full Text] [Related]
3. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
[TBL] [Abstract][Full Text] [Related]
4. An update on laboratory assessment for direct oral anticoagulants (DOACs).
Gosselin RC; Adcock DM; Douxfils J
Int J Lab Hematol; 2019 May; 41 Suppl 1():33-39. PubMed ID: 31069969
[TBL] [Abstract][Full Text] [Related]
5. Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know.
Conway SE; Hwang AY; Ponte CD; Gums JG
Pharmacotherapy; 2017 Feb; 37(2):236-248. PubMed ID: 27983747
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples.
Sevenet PO; Cucini V; Hervé T; Depasse F; Carlo A; Contant G; Mathieu O
Int J Lab Hematol; 2020 Oct; 42(5):636-642. PubMed ID: 32567799
[TBL] [Abstract][Full Text] [Related]
7. Measurement and reversal of the direct oral anticoagulants.
Samuelson BT; Cuker A
Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
9. Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants.
Ten Cate H; Henskens YM; Lancé MD
Vasc Health Risk Manag; 2017; 13():457-467. PubMed ID: 29263674
[TBL] [Abstract][Full Text] [Related]
10. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
[TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulants: new drugs and new concepts.
Levy JH; Spyropoulos AC; Samama CM; Douketis J
JACC Cardiovasc Interv; 2014 Dec; 7(12):1333-51. PubMed ID: 25523529
[TBL] [Abstract][Full Text] [Related]
12. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
Desai NR; Cornutt D
Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
[TBL] [Abstract][Full Text] [Related]
14. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
[TBL] [Abstract][Full Text] [Related]
15. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
[TBL] [Abstract][Full Text] [Related]
16. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
18. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.
Adcock DM; Gosselin R
Thromb Res; 2015 Jul; 136(1):7-12. PubMed ID: 25981138
[TBL] [Abstract][Full Text] [Related]
19. Laboratory measurement of the direct oral anticoagulants.
Dale BJ; Chan NC; Eikelboom JW
Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
[TBL] [Abstract][Full Text] [Related]
20. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.
Samuelson BT; Cuker A; Siegal DM; Crowther M; Garcia DA
Chest; 2017 Jan; 151(1):127-138. PubMed ID: 27637548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]